GlassScriptPhysician profile
Christopher T Aleman
NPI 1669466819
$3,282.28
in general payments reported to CMS, 2019-2025
21 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $20.45 · 2021: $56.62 · 2022: $367 · 2023: $601 · 2024: $884 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,639 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,639.03 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $475.22 | 2019-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $463.17 | 2023-2025 | Adbry |
| Janssen Biotech, INC. | $292.74 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $281.40 | 2022-2025 | |
| Genzyme Corporation | $275.97 | 2022-2025 | |
| Incyte Corporation | $216.98 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $173.48 | 2019-2025 | Nemluvio, Aklief |
| Ucb, INC. | $171.73 | 2023-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $159.31 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $147.57 | 2020-2023 | Dupixent |
| Lilly USA, LLC | $129.04 | 2022 | |
| Ani Pharmaceuticals, INC. | $116.07 | 2023-2025 | Purified Cortrophin Gel |
| Sun Pharmaceutical Industries INC. | $95.26 | 2024-2025 | |
| Blueprint Medicines Corporation | $66.35 | 2024-2025 | Ayvakit |
| Amgen INC. | $58.38 | 2025 | Otezla |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $56.99 | 2022-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.40 | 2023 | Spevigo |
| Pfizer INC. | $18.89 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $15.94 | 2023 | Valchlor |
| Strata Skin Sciences, INC. | $13.40 | 2024 | Xtrac |
| Organon LLC | $1.99 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Aleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.